Praxis Precision Medicines (PRAX) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
9 Jul, 2026Executive summary
Four clinical programs are advancing toward registrational phases by 2025, with multiple late-stage readouts and regulatory filings expected in the next few years.
Lead program ulixacaltamide is in two phase III Essential3 trials for essential tremor, with top-line results expected in 2H 2024 and NDA filing planned for 2025.
PRAX-628, a next-generation epilepsy treatment, is in late-stage development with the ENERGY program, including RADIANT and POWER studies, with topline results for the first efficacy study expected in H1 2025.
Relutrigine (PRAX-562) is in phase II EMBOLD studies for pediatric DEEs (SCN2A, SCN8A), with topline results expected in Q3 2024.
Elanersen (PRAX-222) global registration study initiated in Brazil, with expansion to Europe and the US planned.
Financial highlights
Q2 2024 operating expenses were $37.8 million: $27.3 million for R&D and $10.6 million for G&A.
Net loss for Q2 2024 was $32.7 million, compared to $34.3 million in Q2 2023; net loss for six months was $72.2 million.
Cash, cash equivalents, and marketable securities totaled $433.8 million at June 30, 2024, up from $81 million in December 2023, mainly due to public offerings.
Collaboration revenue was $0.4 million in Q2 2024, down from $0.8 million in Q2 2023.
Cash runway extends into 2027, funding all ongoing studies to their readouts.
Outlook and guidance
Essential3 phase III top-line results expected in late 2024, with NDA filing planned for 2025.
PRAX-628 RADIANT study top-line results expected in H1 2025; POWER-1 and POWER-2 phase III studies to follow.
Relutrigine EMBOLD phase II results expected in Q3 2024.
Elanersen global registration study to expand to Europe and US later in 2024.
Latest events from Praxis Precision Medicines
- Ulixacaltamide nears its PDUFA as commercial readiness and pipeline catalysts advance.PRAX
UBS Global Biopharma Conference 2026 - Two near-term launches anchor a pipeline with >$20B in peak-sales guidance.PRAX
Investor Day 2026 - Ulixacaltamide nears a January decision as launches and pipeline programs advance.PRAX
3rd Annual Guggenheim Healthcare Innovation Conference - Two NDAs near FDA decisions as $1.3B in liquidity supports operations into 2028.PRAX
Q3 2026 - $1.4B cash, late-stage FDA reviews, and commercial readiness drive 2027 launch plans.PRAX
Q2 2026 - Four CNS therapies with blockbuster potential target >$20B peak sales by 2028.PRAX
Corporate presentation - Pivotal epilepsy studies and a robust pipeline set up multiple clinical catalysts through early 2026.PRAX
Jefferies Global Healthcare Conference 2025 - Accelerated clinical and regulatory strategies are driving earlier market entry for key therapies.PRAX
Fireside Chat - Two NDAs filed, strong clinical data, and $1.5B cash position support 2026 launches.PRAX
Q4 2025